Clinical Trials
2 trialsNCT01109069 2020-05-27
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Pharmacyclics LLC.
Phase 2 Completed
NCT02129062 2017-01-16
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated